why choose us

First received: August 21, 2023

Clinical Trial: Supraphysiological Androgen to Enhance Chemotherapy Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Castration-Resistant Prostate Carcinoma

Study Type: INTERVENTIONAL


Official Title: SPECTRA: SupraPhysiological Androgen to Enhance Chemotherapy TReatment Activity

Brief Summary: This phase II trial studies how well giving testosterone at levels higher than normally found in the body (supraphysiological) works to enhance chemotherapy treatment in patients with prostate cancer that has progressed despite being previously treated with androgen therapies and has spread from where it first started (prostate) to other places in the body (metastatic castration-resistant prostate cancer).In patients that have developed progressive cancer in spite of standard hormonal treatment, administering…

Read more